ICML 2021 | Linking the diagnosis-to-treatment interval with ctDNA
Ash Alizadeh
• 17 Jun 2021
Ash Alizadeh, MD, PhD, Stanford Comprehensive Cancer Center, Stanford, CA, discusses the connection between the diagnosis-to-treatment interval (DTI) and circulating tumor DNA (ctDNA) levels in diffuse large B-Cell lymphoma (DLBCL). A shorter DTI has been previously associated with worse patient outcomes. In an analysis of patients receiving standard care and in the Phase III PETAL trial (NCT00554164), a shorter DTI and high ctDNA levels accurately represented baseline tumor burden. Measuring ctDNA levels can consequently be used in a pre-clinical setting by effectively grouping patients in clinical trials. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
